

Oncology Today with Dr Neil Love: Newly Approved Agents in HER2-Positive Metastatic Breast Cancer**THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 1. Results of the Phase II HER2CLIMB trial evaluating tucatinib versus placebo in combination with trastuzumab/capecitabine for patients with previously treated HER2-positive breast cancer and brain metastases demonstrated which of the following outcomes?**
 - Similar overall survival on both study arms
 - Improvement in overall survival with tucatinib
- 2. Which of the following conditions was reported as an adverse event of special interest in the Phase II DESTINY-Breast01 trial of trastuzumab deruxtecan for previously treated HER2-positive metastatic breast cancer (mBC)?**
 - New secondary cancer
 - Ocular toxicity
 - Interstitial lung disease
- 3. The Phase III NALA trial evaluating neratinib with capecitabine versus lapatinib with capecitabine for patients with HER2-positive mBC previously treated with 2 or more HER2-directed therapies demonstrated which of the following outcomes on the neratinib arm?**
 - Improvement in progression-free survival (PFS) only
 - Delayed time to intervention for CNS disease only
 - Both improvement in PFS and delayed time to intervention for CNS disease
- 4. What did the results from the Phase III SOPHIA study demonstrate regarding PFS with margetuximab/chemotherapy compared to trastuzumab/chemotherapy for patients with previously treated HER2-positive mBC?**
 - Significant improvement with margetuximab/chemotherapy
 - Significant improvement with trastuzumab/chemotherapy
 - Similar PFS on both arms